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Abstract
Oral bisphosphonates reduce fracture risk in osteoporotic patients but are often associated with
poor compliance, which may impair their antifracture effects. This post-hoc analysis assessed the
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time-to-onset and persistence of the antifracture effect of zoledronic acid, a once-yearly
bisphosphonate infusion, in women with osteoporosis.
Data from 9355 women who were randomized in two placebo-controlled pivotal trials were
included. Endpoints included reduction in the rate of any clinical fracture at 6, 12, 18, 24, and 36
months in the zoledronic acid group compared with placebo, and the year-by-year incidence of all
clinical fractures over 3 years. Cox proportional hazards regression was used to determine the
timing of onset of antifracture efficacy. A generalized estimating equation model was used to
assess fracture reduction for the 3 consecutive years of treatment, thereby evaluating persistence of
effect. Safety results from women in the two studies were collated. Zoledronic acid reduced the
risk of all clinical fractures at 12 months (hazard ratio, 0.75; 95% confidence interval [CI], 0.61–
0.92; p=0.0050) with significant reductions maintained at all subsequent timepoints. Year-by-year
analysis showed that zoledronic acid reduced the risk for all clinical fractures compared with the
placebo group in each of the 3 years (year 1: odds ratio [OR], 0.74, 95% CI, 0.60–0.91, p=0.0044;
year 2: OR, 0.53, 95% CI, 0.42–0.66, p<0.0001; year 3: OR, 0.61, 95% CI, 0.48–0.77, p<0.0001).
This antifracture effect was persistent over 3 years, with the reductions in year 2 and 3 slightly
larger than in year 1 (p=0.097).
This analysis shows that zoledronic acid offers significant protection from clinical fractures as
early as 12 months. When administered annually, its beneficial effects persist for at least 3 years.
Keywords
fractures; postmenopausal osteoporosis; reaction time; zoledronic acid; bone mineral density
Introduction
Oral bisphosphonates, which are frequently used for the treatment of osteoporosis, have
been widely shown to provide fracture protection for women with osteoporosis.(1-6)
However, the dosing requirements associated with oral administration of these drugs may
reduce patient compliance, thereby affecting the time-to-onset and the persistence of
antifracture effect.(7,8) Clinical studies have shown that oral bisphosphonates can reduce
fracture risk within 1 year of initiation of therapy. Risedronate significantly reduced
vertebral and nonvertebral fracture risk within 6 months of initiation,(6,9) and alendronate
significantly reduced the risk of clinical vertebral, any clinical and nonvertebral fractures
within 12, 18 and 24 months, respectively.(5) These results, however, are taken from clinical
trials, where treatment compliance is higher than in real-world settings. The time-to-onset of
these therapies in clinical practice may, therefore, be different.
A waning of the antifracture effect with oral bisphosphonates over time may also be due to
poor compliance. Studies have shown that compliance with daily, weekly or monthly oral
bisphosphonate treatment was suboptimal even after one year of treatment.(10,11) Given that
poor compliance is associated with increased fracture risk,(10,11) it is possible that some
patients prescribed with an oral bisphosphonate may experience a decline in fracture
protective effect over time. With strontium ranelate, there were numerical between-year
differences in fracture risk reductions over the Spinal Osteoporosis Therapeutic Intervention
(SOTI) study period, suggesting a potential waning of antifracture effect over time.(13)
Nevertheless, year-by-year analyses have not been published for any of these therapies and
no conclusions can be drawn about potential loss of efficacy associated with suboptimal
adherence.
Zoledronic acid is a bisphosphonate that is administered once yearly, by intravenous
infusion. The antifracture efficacy of zoledronic acid has been demonstrated in the Health
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Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial
(HORIZON-PFT) and the HORIZON Recurrent Fracture Trial (HORIZON-RFT), which
showed that zoledronic acid 5 mg significantly reduced fracture risk in postmenopausal
women with osteoporosis and in men and women with prior low-trauma hip fracture.(14,15)
However, neither of these studies investigated the time-to-onset or the year-by-year
antifracture effect of zoledronic acid. This analysis pooled data from all female patients in
the HORIZON-PFT and -RFT to examine the time-to-onset of antifracture efficacy with
zoledronic acid and to evaluate the persistence of this effect, by analyzing the incidence of
clinical fractures within each year of treatment.
Methods
Study design and patients
We performed a pooled post-hoc analysis of data from all women who were randomized in
the multinational randomized, double-blind, placebo-controlled HORIZON-PFT and
HORIZON-RFT. Full methods have been published previously(14,15) but are summarized
here in brief. The HORIZON-PFT enrolled postmenopausal women aged 65–89 years who
had either a femoral neck T-score ≤–2.5 or a T-score ≤–1.5 plus radiological evidence of at
least two mild or one moderate vertebral fracture at baseline.(14) HORIZON-RFT enrolled
patients aged ≥50 years who had undergone surgical repair of a hip fracture that had been
sustained with minimal trauma (i.e. a fall from standing height or lower) in the previous 90
days.(15) Previous use of bisphosphonates with sufficient washout was permitted.
In each study, patients received a 15-minute intravenous infusion of zoledronic acid 5 mg or
placebo. In the HORIZON-PFT, treatments were administered at baseline, 12 and 24
months, and patients monitored for a total of 3 years.(14) In the HORIZON-RFT, treatments
were administered within 90 days after surgical repair of the hip fracture and every 12
months thereafter for the duration of the study (median duration of follow-up, 1.9 years).(15)
Patients also received supplemental calcium and vitamin D for the duration of the trial in
which they were enrolled.
Both studies were reviewed by the Independent Ethics Committee or Institutional Review
Board at each participating centre and were conducted according to the ethical principles of
the Declaration of Helsinki (1989)(16) and local applicable laws and regulations. Informed
consent was obtained from all patients.
Endpoints for this analysis
The endpoints for the time-to-onset of antifracture effect analysis were the cumulative
reductions in the rate of any clinical, clinical vertebral and nonvertebral fracture (excluding
facial/skull and digital fractures [fractures due to excessive trauma were also excluded in
subjects enrolled in the HORIZON-PFT]) at 6, 12, 18, 24, and 36 months in the zoledronic
acid group compared with the placebo group.
The endpoints of the persistence of effect analysis were the year-by-year incidence of these
three fracture types over 3 years. Criteria for fracture classification have been defined
previously.(14,15) Year-by-year incidence of morphometric vertebral fractures was also
analysed for patients in the HORIZON-PFT. Definition of an incident morphometric
vertebral fracture was described previously.(14)
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Statistical analysis
Efficacy
Time-to-onset of antifracture effect: Kaplan-Meier analysis was used to determine the
cumulative proportion of patients with each type of fracture at individual timepoints. A Cox
proportional hazards regression model, stratified by study (HORIZON-PFT or HORIZON-
RFT), was used to determine the statistical significance at each timepoint (6, 12, 18, 24, or
36 months) of the between-treatment difference in the cumulative incidence of each
category of fracture (any clinical fracture, clinical vertebral fracture, nonvertebral fracture).
The time-to-onset was defined as the first timepoint at which results showed a significant
difference between treatment groups (at p<0.05). Additional analyses adjusted for age and
number of infusions were also performed to account for differences between the HORIZON-
PFT and HORIZON-RFT. All patients were included at all timepoints.
Persistence of antifracture effect: Persistence of antifracture effect over time was
investigated by determining the incidence of each type of fracture (any clinical, clinical
vertebral or nonvertebral, morphometric vertebral) in each treatment group within each year
of the studies (years 1, 2, and 3). Determination of fracture incidence was subject to the
following rules to ensure that the data were not cumulative:
• A patient who experienced a new fracture in more than 1 year was recorded in each
of those years;
• A patient who experienced multiple fractures within the same year was recorded
only once in that year;
• A patient who experienced a fracture in 1 year of the study but not in a subsequent
year was recorded only in the year in which the patient fractured.
The clinical fracture (any clinical, clinical vertebral or nonvertebral fractures, excluding
facial/skull and digital fractures [fractures due to excessive trauma were also excluded in
subjects enrolled in the HORIZON-PFT]) incidence data were evaluated using a generalized
estimating equation model with study, treatment, year, and treatment-by-year interaction as
factors. Additional analyses adjusted for age and number of infusions were also performed
to account for differences between the HORIZON-PFT and HORIZON-RFT. The
morphometric vertebral fracture incidence data from in the HORIZON-PFT were evaluated
using a generalized estimating equation model with prevalent fracture status, treatment,
year, and treatment-by-year interaction as factors. All patients were included up to the time
of last visit. The treatment-by-year interaction p-value assessed the year-by-year difference
of treatment effect (with p<0.1 indicating a possible interaction). The generalized estimating
equation model was also used to generate an estimate of the odds ratio for fracture
(zoledronic acid vs. placebo) for each year of the study. Compound symmetry was assumed
for the error structure of this study.
Results
Data from 9355 women were included in the analysis, including 1619 women who were
randomized in the HORIZON-RFT and 7736 postmenopausal women who were randomized
in the HORIZON-PFT. Baseline characteristics were similar between treatment groups in
both the HORIZON-PFT and -RFT (Table 1).
Time-to-onset of antifracture effect
The risk of any clinical fracture was significantly reduced with zoledronic acid treatment at
12 months (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.61–0.92; p=0.0050).
This significant fracture risk reduction was maintained at all subsequent time points (Figure
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1A). There was also a trend towards a reduction in risk after 6 months (HR, 0.77; 95% CI,
0.57–1.03; p=0.0800).
The pattern of risk for clinical vertebral fractures was similar to that for any clinical fracture,
with a significant reduction evident at month 12 (HR, 0.43; 95% CI, 0.24–0.77; p=0.0035)
(Figure 1B), and a trend towards reduction in risk at 6 months (HR, 0.47; 95% CI, 0.21–
1.04; p=0.0553).
A trend towards a reduction in nonvertebral fracture risk was evident from 6 months
onwards but this did not become statistically significant until 18 months after treatment
initiation (HR, 0.77; 95% CI, 0.64–0.92; p=0.0049; Figure 1C).
Similar results were seen for additional analyses adjusted for age and number of infusions.
Significant fracture risk reductions with zoledronic acid were seen at 12 months for any
clinical fractures (p=0.0039) and clinical vertebral fractures (p=0.0049), and at 18 months
for nonvertebral fractures (p=0.0036).
Persistence of antifracture effect
The incidence of clinical fractures was significantly lower in the zoledronic acid group than
in the placebo group in each of the 3 years, although the treatment-by-year interaction
suggested a potential interaction (p=0.097). The odds ratio (OR) for zoledronic acid
compared with placebo was 0.74 in year 1 (95% CI, 0.60–0.91; p=0.0044), 0.53 in year 2
(95% CI, 0.42–0.66; p<0.0001), and 0.61 in year 3 (95% CI, 0.48–0.77; p<0.0001)[Figure
2]. The overall OR of any clinical fracture over 3 years for zoledronic acid compared with
placebo was 0.62 (95% CI: 0.54–0.71; p<0.0001).
The incidence of clinical vertebral fractures was also significantly lower in the zoledronic
acid group than the placebo group in each of the 3 years (Figure 2). A slightly higher
reduction in the incidence of clinical vertebral fracture with zoledronic acid was seen at year
2 compared with years 1 and 3, resulting in a significant between-year difference in
treatment effect (p=0.0082). The overall risk of clinical vertebral fracture over 3 years was
significantly lower in the zoledronic acid group than in the placebo group (OR, 0.25; 95%
CI, 0.16–0.38; p<0.0001).
Zoledronic acid reduced the risk for nonvertebral fractures compared with placebo over 3
years (OR, 0.70; 95% CI, 0.61–0.81; p<0.0001). Year-by-year analysis showed that this
nonvertebral fracture protective effect was significant in years 2 (p=0.0003) and 3
(p=0.0009) but not in year 1 (p=0.0921; Figure 2). There was no significant between-year
difference in the effect of zoledronic acid on nonvertebral fractures (interaction p=0.2167).
For the additional analyses adjusted for age and number of infusions, zoledronic acid was
associated with significantly lower risks for any clinical and clinical vertebral fractures at
each of the 3 years (p<0.005 for each year for both fracture types), with ORs at year 2
smaller than those at year 1 or 3 (any clinical fracture, interaction p=0.0971; clinical
vertebral fracture, interaction p=0.0082). Nonvertebral fracture incidences were also
significantly lower in the zoledronic acid group than the placebo group in year 2 and 3
(p<0.001) and there was no significant between-year difference in the fracture protective
effect of zoledronic acid over 3 years (interaction p=0.2162).
Among patients in the HORIZON-PFT and consistent with the published data, zoledronic
acid significantly reduced the risk of new morphometric vertebral fracture compared with
placebo. This reduction was significant at each of the 3 years according to the year-by-year
analysis (p<0.001 for all). However, the OR of new morphometric vertebral fracture at year
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2 and 3 were smaller than that at year 1 (0.18 and 0.27 vs. 0.40), which gave a significant
between-year difference (interaction p=0.0221).
Discussion
This analysis of pooled data from two multinational, randomized, double-blind, placebo-
controlled trials suggests that annual administration of zoledronic acid reduces the risk of all
clinical fractures and of clinical vertebral fractures within the first year after administration,
and the effect is persistent over at least 3 years. Year-by-year analysis also showed that
zoledronic acid significantly reduced new morphometric vertebral fracture in each of the 3
years of the HORIZON-PFT. Once-yearly infusions of zoledronic acid reduce the risk for
nonvertebral fracture within 18 months of treatment initiation, with the effect maintained at
all subsequent time points. The difference between the onset of effect with zoledronic acid
in clinical vertebral and nonvertebral fracture is consistent with that seen with other
antiresorptive agents, such as alendronate.(5) A possible explanation is that the rapid
reduction in bone resorption seen with potent antiresorptive agents(17) is sufficient to
decrease risk of vertebral fracture whereas an increase in BMD, which requires more time
after initial exposure to therapy, is required to decrease risk of nonvertebral fracture.
Clinical trials of skeletal antiresorptive agents typically evaluate antifracture efficacy by
determining the cumulative fracture incidence or risk reduction from baseline to end of
study. While this allows the assessment of overall efficacy over a treatment course, it does
not allow identification of a difference in treatment efficacy between different treatment
intervals (year 1 vs. year 2, etc.). Consequently, it is difficult to assess whether there is a
differential effect of the therapy in the earlier and later years of the study. Persistence of
antifracture effect has been investigated for raloxifene in an analysis that compared the
treatment effects in study year 4 with cumulative results from years 1 to 3.(18) Although the
study confirmed that the reductions in fracture continued for at least as long as 4 years,
because cumulative results were used for the first 3 years, the year-on-year therapeutic effect
during the initial course of treatment could not be determined. In the SOTI trial, strontium
ranelate reduced vertebral fracture risk by 49% by the end of year 1, 41% by year 3 and 35%
by year 4.(13) Whilst there was no direct year-by-year comparison, the numerical differences
may suggest a potential waning of antifracture effect over time.
The current analysis, the first year-by-year analysis with an osteoporosis agent, has shown
that zoledronic acid demonstrates consistently significant year-on-year risk reduction for any
clinical fracture and clinical vertebral fracture. The year-by-year interaction p-value for any
clinical fracture suggests a potential difference in zoledronic acid’s antifracture effect
between years. However, the overlapping CIs of the year-by-year treatment effect and that
the OR estimates were slightly lower in year 2 and 3 than in year 1, confirms that the
antifracture effect of zoledronic acid does not decrease over time. For clinical vertebral
fracture, a greater reduction in the incidence of clinical vertebral fracture with zoledronic
acid was seen at year 2 compared with year 1 and 3. Similar results were seen with
morphometric vertebral fractures among patients in the HORIZON-PFT. We cannot
determine whether these larger reductions seen are clinically meaningful or a chance
finding. Given that the differences are small and the year 3 findings were similar to year 1, it
suggests that there is no waning of effect over time with zoledronic acid.
The persistence of zoledronic acid’s antifracture effect may be due to a number of factors.
Zoledronic acid has a higher adsorption affinity constant for hydroxyapatite, which may
contribute to a longer duration of effect and allow less frequent dosing than other clinically
used bisphosphonates.(19) Treatment compliance probably plays a major role in the
persistence of antifracture effect demonstrated for zoledronic acid in this study. As the
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dosing schedule of zoledronic acid is once-yearly, it is anticipated that the good compliance
associated with zoledronic acid in clinical trials will translate into the ‘real-world’ setting.
This contrasts with daily, weekly, or monthly oral bisphosphonate dosing regimens which
are, on balance, much more difficult for patients to maintain.(7,11,12,20,21) A recent study in
22,363 new users of weekly or monthly bisphosphonates found 57% of subjects were
noncompliant after 12 months.(11) Treatment non-compliance has been shown to be
associated with reduced antifracture efficacy compared with full compliance.(10,12,20–24) For
instance, in a study that included bisphosphonate-naïve patients who were prescribed with
daily or weekly alendronate, it was found that each 1% decrease of the medication
possession ratio (MPR) was associated with an 0.4% increase in risk of hip fracture at 12
months.(10) A separate study showed that for oral bisphosphonates with a daily or weekly
dosing regimen, noncompliant use was associated with a 45% increased fracture risk
compared with compliant use (defined as MPR ≥80%).(23) A recent review of the
consequences of nonadherence to osteoporosis therapy also concluded that patients who
were noncompliant with treatment have increased risk of fracture regardless of the efficacy
of the treatment prescribed.(24) Furthermore, compliance with oral bisphosphonate therapy
typically decreases with time after treatment initiation,(21) a factor that could lead to lack of
persistence of antifracture effect.
This post-hoc analysis has limitations and the findings should be interpreted in the context
of its design. The results for each year may not be directly comparable: the characteristics of
patients at the start of years 2 and 3 differ from those at baseline and may no longer be
comparable between randomized groups; and the patient numbers and populations at years
1, 2 and 3 differ due to the different lengths of follow-up of patients in the two studies. In
addition, the wide confidence intervals (as seen in Figure 2) suggest that the analyses may
not be optimally powered given that the original studies were designed to evaluate
cumulative effects. Specifically, the lack of statistical significance for any clinical fracture
and clinical vertebral fracture at 6 months is likely related to sample size and the limited
number of fractures for these outcomes at this early time point. However, these limitations
should not detract from the study’s main findings, which demonstrate the early onset and
persistence of zoledronic acid’s antifracture effect. Future analyses that could add to our
knowledge of the time-to-onset and duration of efficacy of this and other bisphosphonates
include retrospective analyses involving larger groups of patients with the same condition or
involving only male or mixed-sex populations, as well as a prospective trial specifically
designed to investigate the year-on-year antifracture effects of bisphosphonates.
Conclusions
This analysis showed that in women with osteoporosis or a recent low-trauma hip fracture,
zoledronic acid significantly reduced clinical fracture risk after one to two doses of therapy.
With repeated dosing, zoledronic acid had a persistent year-by-year therapeutic effect for at
least 3 years.
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Figure 1.
Kaplan-Meier plots of cumulative all clinical (A), clinical vertebral (B) and nonvertebral
fracture (C) event rates from month 0 to month 36 in female patients in HORIZON-PFT and
HORIZON-RFT.
Bracketed values are 95% confidence intervals.
HORIZON-PFT, Health Outcomes and Reduced Incidence with Zoledronic Acid Once
Yearly Pivotal Fracture Trial; HORIZON-RFT, Health Outcomes and Reduced Incidence
with Zoledronic Acid Once Yearly Recurrent Fracture Trial; HR, hazard ratio; PBO,
placebo; ZOL, zoledronic acid.
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Figure 2.
Incidence rates and odds ratio estimates of various types of clinical fractures in patients
receiving zoledronic acid versus those receiving placebo in HORIZON-PFT and
HORIZON-RFT female patients.
*Include women from the HORIZON-PFT only; new morphometric vertebral fracture data
were not collected in the HORIZON-RFT.
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Table 1
Baseline patient characteristics and demographics in HORIZON-PFT patients and in female patients enrolled
in the HORIZON-RFT
HORIZON-PFT* HORIZON-RFT
Variable Placebo,N=3861
Zoledronic acid,
N=3875
Placebo,
N=802
Zoledronic acid,
N=817
Age, years ±SD 73.0±5.40 73.1±5.34 75.2±9.60 75.0±9.15
Body mass index,
kg/m2±SD 25.4±4.3 25.1±4.3 24.8±4.57 24.8±4.48
Region, n (%)
  Western Europe 1162 (30.1) 1160 (29.9) 270 (33.7) 279 (34.1)
  Eastern Europe 772 (20.0) 774 (20.0) 195 (24.3) 210 (25.7)
  North America 765 (19.8)† 766 (19.8)† 229 (28.5) 216 (26.4)
  Latin America 622 (16.1) 625 (16.1) 108 (13.5) 112 (13.7)
  Asia 540 (14.0) 550 (14.2) NA NA
Femoral neck T-score, n (%)
 ≤−2.5 2734 (70.8) 2814 (72.6) 342 (42.6) 354 (43.3)
 >2.5 to −1.5 1073 (27.8) 1002 (25.9) 277 (34.5) 269 (32.9)
 >1.5 38 (1.0) 35 (0.9) 84 (10.5) 91 (11.1)
  Missing 16 (0.4) 24 (0.6) 99 (12.3) 103 (12.6)
*29 patients from the HORIZON-PFT were excluded from this pooled analysis as they were enrolled at a site whose participation was terminated
during the study.
†
Plus Oceania.
BMD, bone mineral density; HORIZON-PFT, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial;
HORIZON-RFT, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Recurrent Fracture Trial; NA, not applicable; SD,
standard deviation.
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